Aberrations in the cyclin D1/E1–cyclin-dependent kinase (CDK2/4/6)–retinoblastoma (RB) pathway can promote an aggressive ovarian cancer phenotype. This evidence concerns the gene CDK2 and ovarian carcinoma.